Anti-BCMA-Anti-CD3 IgG Bispecific Antibody

Only %1 left

Catalog #

101968

As low as $370 *

Cat # Size Price*

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Anti-BCMA-Anti-CD3 IgG format bispecific antibody is a purified recombinant human bispecific antibody with T cell Engager. This bispecific antibody has been tested in a functional reporter assay using NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621) in the presence of BCMA CHO Recombinant Cell Line (BPS Bioscience #79500-H) that overexpress BCMA.

●

Synonyms

cd3, cd-3, cluster of differentiation 3, Tumor necrosis factor receptor superfamily member 17, B-cell maturation protein, CD269, TNFRSF17, BCM, BCMA

●

Product Data Gallery

4-20% SDS-PAGE Coomassie Staining

Activation of NFAT Luciferase Reporter Jurkat cells by Anti-BCMA-Anti-CD3 IgG in the presence of BCMA-CHO cells

Product Info

Storage and Usage

Citations

Species

Human

Host Species/Expression System

HEK293

Purity

≥90%

Format

Aqueous buffer solution

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, and 2.2 mM KCl

CD3 Heavy Chain: 50 kDa; CD3 Light Chain: 23 kDa; BCMA Heavy Chain: 49 kDa; BCMA Light Chain: 23 kDa

UniProt #

BCMA: Q02223

Background

B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). It is found in mature B lymphocytes, and its cleaved form (sBCMA) is found at elevated levels in patients with multiple myeloma (MM). It has also been implicated in leukemia and lymphoma. BCMA is an attractive target for CAR-T based cancer therapy due to its pattern of expression, and studies have resulted in two clinical trials using CAR-T based therapy products (ALL-715 and JNJ-4528) being approved for the treatment of MM. Additionally, BCMA has been extensively used in the context of bis-specific antibodies that bring together cancer cells and T cells. Just recently a new BCMA based bispecific antibody, Elrexfio), has been approved for the treatment of patients with refractory MM that had four prior lines of therapy. Further developments and studies into BCMA will open more cancer therapy avenues.

Storage/Stability

At least 12 months at -80°C.

Instructions for Use

Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.

Applications

This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-BCMA-anti-CD3 IgG format bispecific antibody can be used for studying BCMA⁺ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as NFAT Luciferase Reporter Jurkat Cell Line (BPS Bioscience #60621).

Shipping Temperature

-80°C

Warnings

Avoid freeze/thaw cycles

Scientific Category

Cancer Therapy Target

Regulatory Status

Research Use Only